PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 151 filers reported holding PROGENICS PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is 1.60 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $182,000 | -0.5% | 35,800 | -1.3% | 0.01% | 0.0% |
Q3 2019 | $183,000 | -78.8% | 36,281 | -74.1% | 0.01% | -78.4% |
Q2 2019 | $863,000 | +22.2% | 139,900 | -8.1% | 0.05% | +27.5% |
Q1 2019 | $706,000 | +256.6% | 152,200 | +472.1% | 0.04% | +700.0% |
Q2 2015 | $198,000 | – | 26,606 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadfin Capital, LLC | 1,583,925 | $8,007,000 | 1.48% |
Phocas Financial Corp. | 1,022,708 | $5,169,000 | 0.55% |
RICE HALL JAMES & ASSOCIATES, LLC | 1,776,490 | $8,980,000 | 0.32% |
FARALLON CAPITAL MANAGEMENT LLC | 7,350,000 | $37,154,000 | 0.28% |
NEXPOINT ASSET MANAGEMENT, L.P. | 716,880 | $3,624,000 | 0.23% |
J. Goldman & Co LP | 499,698 | $2,526,000 | 0.19% |
PINNACLE ASSOCIATES LTD | 1,257,098 | $6,355,000 | 0.15% |
CARILLON TOWER ADVISERS, INC. | 3,948,024 | $19,957,000 | 0.14% |
EAGLE ASSET MANAGEMENT INC | 4,504,094 | $22,768,000 | 0.12% |
Worth Venture Partners, LLC | 32,956 | $167,000 | 0.10% |